SOLICITATION NOTICE
66 -- Covaris S2 High Performance Ultrasonicator
- Notice Date
- 7/17/2009
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-90128-AV
- Archive Date
- 8/11/2009
- Point of Contact
- Ashley L. Virts,
- E-Mail Address
-
virtsa@mail.nih.gov
(virtsa@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR), Genetics Branch plans to procure as a sole source the brand name Covaris S2 High Performance Ultrasonicator with Covaris Inc.; 14 Gill Street, Unit H; Woburn, Massachusetts 01801-1721. This acquisition will be conducted under the procedures for acquiring commercial items authorized in FAR Part 12 and under the authority to use simplified procedures for commercial requirements as provided in FAR 13.501. The North American Industry Classification System code is 334516 and the business size standard is 500 employees. This is not a solicitation for competitive quotations. However, if any interested party believes it can perform the requirement as detailed they may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the contracting office by 11:00 am EST, on July 27, 2009. All questions must be in writing and must be emailed to Ashley Virts at virtsa@mail.nih.gov faxed to (301) 402-4513. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award from the NCI contractors must be registered in the Online Representations and Certifications Applications (ORCA). Please refer to http://orca.bpn.gov In addition; contractors must be registered in the Central Contractor Registration (CCR) www.ccr.gov. No collect calls will be accepted. Please reference NCI-90128-AV on all correspondence. Part I: Background information and description of requirements: The Genetics Branch of the Center for Cancer Research at the National Cancer Institute is engaged in the study of cancer genetics. Investigating genetic alteration and its effect on the development and biology of cancer is an integral function of The Genetics Branch. By using ultra-high throughput, next generation sequencing, and whole-genome high-resolution beadchip reagents, the lab is able to study DNA/promoter interactions, gene expression, methylation status, single nucleotide polymorphism (SNP), and investigate genomic rearrangements at resolutions at informatics levels never before possible. Due to recent and foreseen increases in the demand for second- generation pyrosequencing of human pathogens and/or the host, the Genomics Core facility requires an apparatus for DNA template shearing and disruption of bead emulsions for second-generation DNA sequencing, template library preparation involves production of a random collection of adapter-modified DNA fragments. In some applications, such as variant detection or the re-sequencing of amplicons, a very tight fragment size distribution is required. JUSTIFICATION FOR OTHER THAN FULL AND OPEN COMPETITION: Part II: Facts and Reasons to Justify Other than Full and Open Competition: Statutory Authority Statute: This justification has been prepared under the authority of 41 U.S.C. 253 (c)(1) as set forth in 13.106-1 (b)(1). (b) Soliciting from a single source. (2) For sole source acquisitions of commercial items in excess of the simplified acquisition threshold conducted pursuant to subpart 13.5, the requirements at 13.501(a) apply. No other requirement and/or type for supply or service will satisfy agency need. Justification: Ultrasonic digestion is different from shearing techniques due to its focused acoustic shock waves which is effective for shearing DNA fragments >300bp and intense mixing or disruption of tissues. Process time must be balanced with temperature control to prevent loss of sample integrity. The Covaris Ultrasonicator is advanced compared to standard sonicators in the general market due to vast improvement in the shearing mechanism which is also needed to achieve the level and quality of research required from the established Next-Generation sequencing experiments and methods currently used within the lab. Covaris is the sole source offering shearing formats that to be utilized on pre-established scientific protocol and methods of the Next Generation Sequence Analyzers. They are manufactured to allow for custom design of DNA shearing necessary by out protocols. This custom DNA shearing is in condition essential for Next Generation Sequencers already in place in the Genetics Branch. No other sonication instrument exists in the general lab market place that will work seamlessly with the Next-Generation Sequence Analyzers. Other instruments cannot fragment or shear DNA molecule to a size required by Next Generation protocols and methods. For these reasons, no other source is known to the NCI to comply with the needs of the lab. The following salient characteristics apply to the Covaris S2 High Performance Ultrasonicator: •Adaptive focused acoustic process to produce a controlled acoustic field inside a closed vessel •Dish shaped transducer to converge energy to small localized areas •Utilizes an isothermal process that eliminates any potential temperature aggregation •Utilizes a 500 MHz transducer enabling high frequency focused ultrasonic energy outside the human audible range •Easily configured to various tubes and vials for versatility •Operates using microtubes holding 100ul for reduced sample volume •Utilizes multiple solvents (aqueous, organic) •Rapid, scalable energy to quickly stabilize target molecules •Non-contact processing to avoid tissue disruption for RNA and protein targets
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-90128-AV/listing.html)
- Record
- SN01879301-W 20090719/090718000153-cf7a3df05c68c61cbf7fbad4568c9d81 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |